Long-Term Outcomes of Endoscopic Ultrasound-Guided Coloenterostomy With a Lumen-Apposing Metal Stent for Malignant Small Bowel Obstruction

被引：0

作者：

Gao, Ningjing ^{[1
]}

Ni, Muhan ^{[1
]}

Tang, Dehua ^{[1
]}

Zhang, Xiang ^{[1
]}

Yan, Peng ^{[1
]}

Zhang, Bin ^{[1
]}

Zheng, Ruhua ^{[1
]}

Shen, Yonghua ^{[1
]}

Zhang, Song ^{[1
]}

Zhou, Lin ^{[1
]}

Zhu, Hao ^{[1
]}

Lv, Ying ^{[1
]}

Yang, Hua ^{[1
]}

Shen, Shanshan ^{[1
]}

Wang, Lei ^{[1
]}

机构：

[1] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Gastroenterol, Affiliated Hosp,Med Sch, Nanjing, Jiangsu, Peoples R China

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2025年

基金：

中国国家自然科学基金;

关键词：

endoscopic ultrasound-guided coloenterostomy; long-term outcomes; lumen-apposing metal stent; malignant small bowel obstruction; MANAGEMENT; SURGERY;

D O I：

10.1111/jgh.70011

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and AimsEndoscopic ultrasound-guided coloenterostomy (EUS-CE) using lumen-apposing metal stents (LAMS) has emerged as a potential alternative for the palliative treatment of malignant small bowel obstruction (MSBO). However, the long-term outcomes of EUS-CE remain unclear. This study aimed to assess the efficacy and safety of EUS-CE, focusing on long-term outcomes.MethodsThis retrospective cohort study consecutively included patients who underwent EUS-CE for the palliative treatment of MSBO between July 2022 and December 2023 at a tertiary care hospital in China. The longest follow-up period was 362 days. The primary outcomes were overall survival (OS) and symptom recurrence-free survival (SRFS) period. Secondary outcomes included technique success, clinical success, and adverse events (AEs).ResultsA total of 15 patients underwent EUS-CE for MSBO. Technical success was 100%, and clinical success was 93.3%. AEs occurred in 4 (26.7%) patients: one leak, one bleed, and two cases of diarrhea. The median OS period was 65 days, with a 60.0% rate of 60 days survival. The median SRFS period was 165 days, with a 41.7% rate of symptom recurrence at 60 days. All patients survived 30 days, and no symptom recurrence was observed within 30 days. A prolonged OS period was observed in patients without peritoneal carcinomatosis and those who received additional chemoradiotherapy.ConclusionsEUS-CE is an effective alternative for the palliative treatment of MSBO, demonstrating satisfactory patency and survival benefits based on a long-term cohort.

引用

页数：8

共 19 条

[1] AGA Clinical Practice Update on the Optimal Management of the Malignant Alimentary Tract Obstruction: Expert Review [J].